Home » Strategic Investment from Sichuan Hebang Biotechnology

Strategic Investment from Sichuan Hebang Biotechnology

Strategic Investment from Sichuan Hebang Biotechnology

Strategic Investment

If the Shareholders Approval or any other regulatory approval required for Tranche 2 is not obtained by 31 October 2024, given the company’s history of raising capital to date, the directors are confident of the company’s ability to raise additional funds through a placement, rights issue, SPP, convertible note or other capital raising method previously utilized by the Company, when the unsecured loan is due for repayment, on or around September 2025.

source

Leave a Reply

Your email address will not be published.